Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Prepaid Assets (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Prepaid Assets for 13 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets fell 6.97% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, down 6.97% year-over-year, with the annual reading at $6.2 million for FY2025, 6.97% down from the prior year.
  • Prepaid Assets hit $6.2 million in Q4 2025 for Coherus Oncology, down from $8.0 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $21.9 million in Q3 2022 to a low of $6.2 million in Q4 2025.
  • Historically, Prepaid Assets has averaged $12.3 million across 5 years, with a median of $12.3 million in 2022.
  • Biggest five-year swings in Prepaid Assets: plummeted 54.22% in 2021 and later surged 144.44% in 2023.
  • Year by year, Prepaid Assets stood at $13.7 million in 2021, then surged by 30.51% to $17.9 million in 2022, then crashed by 37.93% to $11.1 million in 2023, then tumbled by 39.63% to $6.7 million in 2024, then dropped by 6.97% to $6.2 million in 2025.
  • Business Quant data shows Prepaid Assets for CHRS at $6.2 million in Q4 2025, $8.0 million in Q3 2025, and $6.7 million in Q2 2025.